Pneumovax 23 market outlook points to steady growth through 2035

The Pneumovax 23 vaccine market is expanding as countries push harder on adult immunization, pneumococcal disease prevention and vaccine access. The Business Research Company says North America led the market in 2025, while urbanization and government vaccination programs are adding momentum worldwide.

Why it matters: - Pneumococcal disease remains a major public health burden, especially for older adults and people with chronic conditions. - Growing demand for preventive care is supporting the market for Pneumovax 23, a vaccine that targets 23 pneumococcal serotypes. - Broader vaccination access could help reduce serious infections such as pneumonia, meningitis and bloodstream infections.

What happened: - The Business Research Company published its Pneumovax 23 Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Pneumovax 23 market has been growing and is expected to keep expanding through 2035. - The report also says North America held the largest regional share of the market in 2025. - The company offers a free sample of the report and the full market report.

The details: - Pneumovax 23 protects against 23 strains of pneumococcal bacteria. - The vaccine is mainly used in older adults and people with certain medical conditions. - The report identifies past growth drivers as broader national immunization policies, higher pneumococcal infection rates among older adults, wider availability of polysaccharide vaccines and more preventive health awareness. - The report lists future growth drivers as more investment in adult vaccination programs, stronger focus on infectious disease prevention, more pharmacy-based immunization services, demand for longer-lasting vaccines and better storage and distribution systems. - Key trends cited in the report include adult and elderly vaccination campaigns, stronger pneumococcal prevention efforts, expanded public health messaging and improved cold-chain management. - The report says rising pneumococcal disease incidence is boosting demand. - In June 2025, the UK Office for Health Improvement and Disparities reported a 16% increase in emergency hospital admissions for pneumonia in England for the year ending 2024, with about 252,912 admissions. - The report also points to urbanization as a growth driver. - A World Bank Group report from April 2023 said about 56% of the global population, or roughly 4.4 billion people, lived in urban areas, with that share projected to approach 70% by 2050. - The World Bank Group also said urban land expansion is expected to add about 1.2 million square kilometers of new urban space by 2030. - Government immunization programs are another driver highlighted in the report. - In July 2024, Gavi said nearly 69 million children received routine immunizations supported by Gavi in 2023. - Gavi also said more than 72 million children in low-income countries benefited from its support by 2024.

Between the lines: - The market thesis is built less on a single new product launch and more on structural demand: aging populations, post-pandemic catch-up vaccination and wider distribution channels. - Pharmacy-based vaccination and improved cold-chain logistics could matter because they make adult immunization easier to access and scale. - The report’s geographic snapshot suggests the strongest current commercial base is in North America, but the demand story is global.

What's next: - The market is expected to benefit from continued expansion of adult vaccination programs and public health campaigns. - Future growth will likely depend on how quickly health systems improve vaccine access, storage and outreach. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, dashboards, hotspot infographics and updated trend analysis.

The bottom line: - Pneumovax 23 sits at the intersection of aging demographics, persistent pneumococcal disease risk and expanding immunization infrastructure, which supports a positive long-term market outlook.